Tags

Type your tag names separated by a space and hit enter

Update on gout and hyperuricemia.
Int J Clin Pract. 2010 Feb; 64(3):371-7.IJ

Abstract

There have been recent advances in the understanding of underlying mechanisms and treatment of gout and chronic hyperuricemia, making this an important time to review the current state of the disease. The goal of this article is to provide a practical review of the current standard of care as well as discuss some new developments in the management. There is an increasing prevalence of gout and hyperuricemia worldwide. Gout confers a significant individual and societal burden and is often under-treated. Appropriate diagnosis and treatment of acute gout should be followed by aggressive and goal-oriented treatment of hyperuricemia and other risk factors. Allopurinol remains as a first-line treatment for chronic hyperuricemia, but uricosuric agents may also be considered in some patients. Febuxostat, a non-purine xanthine-oxidase inhibitor, is a new agent approved for the treatment of hyperuricemia in patients with gout, which may be used when allopurinol is contraindicated. Gout and hyperuricemia appear to be independent risk factors for incident hypertension, renal disease and cardiovascular disease. Physicians should consider cardiovascular risk factors in patients with gout and treat them appropriately and aggressively.

Authors+Show Affiliations

Department of Medicine, Division of Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA. bakerjo@uphs.upenn.eduNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19909378

Citation

Baker, J F., and H Ralph Schumacher. "Update On Gout and Hyperuricemia." International Journal of Clinical Practice, vol. 64, no. 3, 2010, pp. 371-7.
Baker JF, Schumacher HR. Update on gout and hyperuricemia. Int J Clin Pract. 2010;64(3):371-7.
Baker, J. F., & Schumacher, H. R. (2010). Update on gout and hyperuricemia. International Journal of Clinical Practice, 64(3), 371-7. https://doi.org/10.1111/j.1742-1241.2009.02188.x
Baker JF, Schumacher HR. Update On Gout and Hyperuricemia. Int J Clin Pract. 2010;64(3):371-7. PubMed PMID: 19909378.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Update on gout and hyperuricemia. AU - Baker,J F, AU - Schumacher,H Ralph, Y1 - 2009/11/10/ PY - 2009/11/14/entrez PY - 2009/11/17/pubmed PY - 2011/5/13/medline SP - 371 EP - 7 JF - International journal of clinical practice JO - Int J Clin Pract VL - 64 IS - 3 N2 - There have been recent advances in the understanding of underlying mechanisms and treatment of gout and chronic hyperuricemia, making this an important time to review the current state of the disease. The goal of this article is to provide a practical review of the current standard of care as well as discuss some new developments in the management. There is an increasing prevalence of gout and hyperuricemia worldwide. Gout confers a significant individual and societal burden and is often under-treated. Appropriate diagnosis and treatment of acute gout should be followed by aggressive and goal-oriented treatment of hyperuricemia and other risk factors. Allopurinol remains as a first-line treatment for chronic hyperuricemia, but uricosuric agents may also be considered in some patients. Febuxostat, a non-purine xanthine-oxidase inhibitor, is a new agent approved for the treatment of hyperuricemia in patients with gout, which may be used when allopurinol is contraindicated. Gout and hyperuricemia appear to be independent risk factors for incident hypertension, renal disease and cardiovascular disease. Physicians should consider cardiovascular risk factors in patients with gout and treat them appropriately and aggressively. SN - 1742-1241 UR - https://www.unboundmedicine.com/medline/citation/19909378/Update_on_gout_and_hyperuricemia_ DB - PRIME DP - Unbound Medicine ER -